Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triamcinolone for EGFRI-induced rash
NCT03115567Phase 2Terminated
- Sponsor
- Northwestern University
- Start
- Feb 2017
- Primary completion
- Apr 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of triamcinolone acetonide in papulopustular eruption and acneiform rash (2 arms), sponsored by Northwestern University. Primary endpoint: Percentage of Participants With Grade 2 Rash or Higher at 6 weeks. Started Feb 2017; status: terminated.
02
Drugs
triamcinolone acetonide
03
Conditions
papulopustular eruptionacneiform rash
Beyond the preview
Go deeper on NCT03115567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03115567.